Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 2023-05-18 11:53
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 2023-05-18 02:47
Antengene Announces NDA Submission for XPOVIO® in Indonesia 2023-05-17 08:30
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia 2023-03-29 08:30
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China 2023-03-14 12:29
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023-01-03 14:10
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma 2022-12-23 08:30
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting 2022-11-07 14:38
Antengene to Host Research and Development Day on November 15th and 17th, 2022 2022-10-27 11:07
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting 2022-10-08 10:43
Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA 2022-09-19 09:34
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence 2022-09-14 08:30
Antengene to Present at Upcoming Industry Conferences 2022-09-09 14:43
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma 2022-09-01 08:30
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia 2022-08-16 08:30
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma 2022-08-03 08:30
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma 2022-06-27 08:30
Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting 2022-06-01 08:30
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas 2022-05-23 10:10
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China 2022-05-18 15:01
1 2